|Bid||52.65 x 1300|
|Ask||67.35 x 1400|
|Day's Range||66.77 - 68.68|
|52 Week Range||44.27 - 73.69|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||39.46|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.83|
Today we'll evaluate Quidel Corporation (NASDAQ:QDEL) to determine whether it could have potential as an investment...
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
President & CEO of Quidel Corp (30-Year Financial, Insider Trades) Douglas C Bryant (insider trades) sold 71,708 shares of QDEL on 08/30/2019 at an average price of $62.18 a share. Continue reading...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
Quidel (QDEL) delivered earnings and revenue surprises of 0.00% and 0.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2019.
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
President & CEO of Quidel Corp (30-Year Financial, Insider Trades) Douglas C Bryant (insider trades) sold 21,789 shares of QDEL on 07/29/2019 at an average price of $57.78 a share. Continue reading...
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received 510(k) clearance from the Unites States Food and Drug Administration (FDA) to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the qualitative determination of the presence of drug and/or metabolites in human urine of up to 9 drug assays. The test is to be used with Quidel’s Triage® MeterPro instrumented system.
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.